DOCSLIB.ORG

Comparative Dose-Response Study of Three Metered Dose Inhaler

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparative Dose-Response Study of Three Metered Dose Inhaler 62 Thorax 1995;50:62-66 Comparative dose-response study of three anticholinergic agents and fenoterol using a Thorax: first published as 10.1136/thx.50.1.62 on 1 January 1995. Downloaded from metered dose inhaler in patients with chronic obstructive pulmonary disease Akihiko Ikeda, Koichi Nishimura, Hiroshi Koyama, Takateru Izumi Abstract either ipratropium bromide or flutropium Background - Inhaled anticholinergics bromide when used at doses of less than and P agonists are widely used in the treat- six puffs, without apparent side effects. ment of patients with chronic obstructive There were, however, no differences in pulmonary disease (COPD). However, maximal response between these drugs. dosage requirements have not been thor- Fenoterol may have a greater peak bron- oughly evaluated and comparative dose- chodilator effect than the anticholinergic response data for these agents are limited. agents but it causes more adverse effects, Methods - Twenty men with stable COPD even at lower doses. Depending upon the ofmean (SD) age 69-4 (5.8) years and FEVy balance between efficacy and side effects, 0 93 (0.38) litres were studied in ran- oxitropium bromide may be preferred in domised, double blind, crossover, placebo the treatment of patients with COPD. controlled experiments. All ofthe patients (Thorax 1995;50:62-66) received two, four, eight, and 16 puffs of ipratropium bromide (20 tgIpuff), flu- Keywords: chronic obstructive pulmonary disease, ip- ratropium bromide, oxitropium bromide, flutropium tropium bromide (30 tgIpuff), oxitropium bromide, fenoterol. bromide (100 sgIpuff), fenoterol (200 dgi puff), or placebo in random order on five separate days. Doses were administered by a metered dose inhaler at intervals of http://thorax.bmj.com/ 60 minutes to give cumulative doses oftwo, The appropriate use of bronchodilator drugs six, 14, and 30 puffs. Five mg of nebulised improves airflow limitation and reduces dys- salbutamol was administered 60 minutes pnoea in patients with chronic obstructive pul- after the patient had received the final 16 monary disease (COPD). Two classes of puffs of each regimen. Forced expiratory inhaled bronchodilators - anticholinergics and volume in one second (FEVI), forced vital 02 agonists - are available for the management capacity (FVC), heart rate, and blood of COPD. Anticholinergic agents show fewer pressure were measured five minutes be- side effects and often greater efficacy in elderly on September 24, 2021 by guest. Protected copyright. fore each treatment and 30 minutes after patients.'`6 Despite the extensive use of these treatment with nebulised salbutamol. agents, the dosage requirements for patients Results - FEV1 and FVC reached a plateau with COPD have not been clearly established after administration of a cumulative dose and most recommended dosages result in less of 14 puffs ofipratropium bromide (280 tg) than maximal bronchodilation.7-'0 Ipratropium or flutropium bromide (420 tg), and after bromide and oxitropium bromide are widely six puffs of oxitropium bromide (600 ,sg). used, but few reports compare the effects There were no differences with respect to of these drugs in the treatment of COPD. maximum increases in FEVy and FVC Flutropium bromide is a quatemary anti- amongst the three anticholinergic agents. cholinergic derived from atropine and has a However, after six puffs oxitropium brom- pharmacological profile closely related to that ide produced a greater increase in FEVy ofipratropium bromide.'" Flutropium bromide Chest Disease than either ipratropium bromide or flu- also possesses some antihistaminic and anti- Research Institute, tropium bromide. Fenoterol caused a 2 and has been used in Kyoto University, allergic activity Japan 53 Kawara-machi greater increase in both FEV, and FVC for the relief of symptoms of bronchial asthma Shogoin Sakyo-ku, than the three anticholinergic agents after and COPD. There are, however, few controlled Kyoto 606-01, Japan six puffs, as well as a greater increase in studies either assessing the clinical efficacy of A Ikeda bromide or it with other K Nishimura pulse rate. Oxitropium bromide produced flutropium comparing H Koyama a greater increase in pulse rate than the anticholinergic agents. T Izumi other anticholinergics after 14 puffs. The To determine the dosage which produced Reprint requests to: incidence of side effects was dose-related optimal bronchodilation, a cumulative dose- Dr A Ikeda. and notable adverse effects were reported response study comparing the currently avail- Received 11 March 1994 after 30 puffs of ipratropium bromide, 14 able anticholinergic agents (ipratropium brom- Returned to authors 16 June 1994 puffs ofoxitropium bromide, and two puffs ide, flutropium bromide, and oxitropium Revised version received of fenoterol. bromide) and the adrenergic agent fenoterol 2 September 1994 - a Accepted for publication Conclusions Oxitropium bromide pro- was undertaken using metered dose inhaler 10 October 1994 duced a greater bronchodilator effect than in patients with stable COPD. Dose-response study of three anticholinergic agents andfenoterol in stable COPD 63 Methods exhaled to functional residual capacity, the can- SUBJECTS ister was activated. Patients then inhaled very Twenty men with stable COPD were recruited slowly until total lung capacity was reached, at from the outpatient clinic at the Chest Disease which point the breath was held for at least 10 Thorax: first published as 10.1136/thx.50.1.62 on 1 January 1995. Downloaded from Research Institute, Kyoto University. All sub- seconds. To ensure that the trials were double jects fulfilled the following criteria: (1) a history blind, identical metered dose inhaler canisters of more than 20 pack-years of cigarette smok- containing either active drug or placebo were ing; (2) a forced expiratory volume in one prepared in advance, coded, and randomly second (FEV,) of <80% ofthe predicted value, selected. The treatment codes were not re- and a best post-bronchodilator FEVI/forced vealed until all 20 patients had completed the vital capacity (FVC) ratio of less than 0-7; (3) protocols. a history of chronic dyspnoea on exertion with Spirometric testing was performed according or without sputum production and radiological to the methods described in the American evidence of emphysema; (4) no history sug- Thoracic Society's 1987 update.14 Three con- gestive of asthma; (5) no exacerbation of air- secutive flow-volume curves were recorded ways obstruction in the preceding three months with a spirometer (AUTOSPIRO AS-600, Mi- and no heart disease or any other illness; nato Medical Science, Osaka, Japan), which and (6) no treatment with oral or inhaled was precalibrated with a 3-01 syringe before corticosteroids in the preceding four weeks, each day oftesting. The highest FEV, and FVC and no current treatment with any oral from the triplicate measurements were analysed bronchodilators, including theophylline. No and predicted FEV1 and FVC values were cal- patients were current smokers. The study was culated according to the 1993 proposal of the approved by the ethics committee of our in- Japan Society of Chest Diseases."5 stitute and written informed consent was ob- Pulmonary function tests were performed tained from each patient. within the three months preceding the study and at least 12 hours after the administration of bronchodilators had been suspended. In STUDY DESIGN addition to spirometric testing (CHESTAC- The study was performed in a randomised, 65V, Chest, Tokyo, Japan) the functional double blind, placebo controlled, crossover residual capacity was measured by ple- fashion. Testing was started at approximately thysmography (MBR-600, Nihon Kohden, the same time each morning on five separate Tokyo, Japan) and this was combined with the days during a two week period, and the interval inspiratory capacity measured spirometrically between testing ranged from two to four days. to calculate the total lung capacity. The static The patients received two, four, eight, or 16 compliance and airways resistance were also http://thorax.bmj.com/ puffs of: (1) ipratropium bromide (20 ,ug/puff); measured by plethysmography. The carbon (2) flutropium bromide (30 gg/puff); (3) oxi- monoxide diffusing capacity was measured tropium bromide (100 jg/puff); (4) fenoterol using the single breath technique (CHESTAC- (200 gg/puff); and (5) placebo in random 65V). order. Doses were administered by a metered dose inhaler at one hour intervals to give cu- mulative doses of two, six, 14, and 30 puffs. DATA ANALYSIS Five mg of nebulised salbutamol in 1 ml saline Friedman's two way analysis of variance was on September 24, 2021 by guest. Protected copyright. was administered 60 minutes after the patient used to compare differences between the five had received 16 puffs of each regimen. test regimens with respect to FEVy and FVC Spirometric testing was performed initially, 60 (expressed as absolute changes from the base- minutes after each dose (and just before line), and also with respect to pulse rate and the administration of the next dose), and 30 blood pressure (expressed as absolute differ- minutes after the administration of nebulised ences relative to the placebo). When a sig- salbutamol. Pulse rate and blood pressure were nificant difference existed among groups the also measured after at least five minutes of rest Wilcoxon signed rank test was used to identify before each spirometric measurement. Sim- specifically which differences were significant. ultaneously, patients were asked
Load more

Recommended publications
  • Effects of Glycopyrronium on Lung Hyperinflation in COPD Patients Claudio M Sanguinetti1,2
    Sanguinetti Multidisciplinary Respiratory Medicine 2014, 9:19 http://www.mrmjournal.com/content/9/1/19 REVIEW Open Access The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients Claudio M Sanguinetti1,2 Abstract Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation caused by bronchial alterations, small airways disease and parenchymal destruction. In patients with COPD the structural and functional lung alterations can progress more or less rapidly from the initial small airways disease to an overt COPD where a severe expiratory flow limitation takes place. In these conditions, lung hyperinflation develops characterized by increase in functional residual capacity (FRC) and decrease in inspiratory capacity (IC). Thus, IC is an easy and reliable index to monitor lung hyperinflation and to assess the efficacy of bronchodilator drugs. When FRC increases, tidal volume (VT) is located in a more flatted upper part of the P –V curve of the respiratory system and respiratory muscles must sustain a greater elastic workload. Furthermore, due to inadequate time for expiration, there is a positive alveolar pressure at the end of expiration (PEEPi). This represents a further elastic workload for the inspiratory muscles. This impairment of ventilatory mechanics generates dyspnea that in most severely compromised patients occurs also for small efforts causing activity limitation and worst health-related quality of life (HRQoL). Due to these respiratory alterations, bronchodilators are the cornerstone of the long-term treatment of COPD in order to decrease airways resistances, lung hyperinflation and exacerbation rate, and improve patient’s symptoms, exercise tolerance and health status.
    [Show full text]
  • Effects of Replacing Oxitropium with Tiotropium on Pulmonary Function in Patients with COPD: a Randomized Study
    View metadata, citation and similar papers at core.ac.uk ARTICLE IN PRESS brought to you by CORE provided by Elsevier - Publisher Connector Respiratory Medicine (2007) 101, 476–480 Effects of replacing oxitropium with tiotropium on pulmonary function in patients with COPD: A randomized study Cristoforo IncorvaiaÃ, Gian Galeazzo Riario-Sforza, Chiara Pravettoni, Natale Dugnani, Fulvia Paterniti, Laura Pessina, Mario Fumagalli Unit of Pulmonary Rehabilitation, ICP Hospital, via Bignami 1, Viale Molise 69, Milan, Italy Received 3 February 2006; accepted 6 July 2006 KEYWORDS Summary COPD; Background: Inhaled bronchodilators are first line drugs in the treatment of chronic Pulmonary function; obstructive pulmonary disease (COPD). Tiotropium bromide is a recently introduced long- Drug treatment; acting anticholinergic agent able to reduce dyspnoea and COPD exacerbations and to Anticholinergics; improve pulmonary function and quality of life. We designed a study to compare the short- Tiotropium; term efficacy of tiotropium bromide with that of oxitropium bromide in improving Oxitropium pulmonary function in patients with COPD. Methods: Eighty patients were randomized either to continue oxitropium 800 mcg/day or to receive tiotropium 18 mcg/day. Seventy-six (39 in the tiotropium and 37 in the oxitropium group) completed the study. Plethysmography was performed at baseline and after 72 h in all patients. The changes in functional parameters in the two groups were compared by the Mann–Whitney U-test. Results: There were no differences between the two groups regarding age (72.5 vs. 74.2 years), male/female ratio (25/14 vs. 23/14) and pulmonary function at baseline. The changes in spirometric parameters were significantly greater in tiotropium- than in oxitropium-treated patients: mean forced expiratory volume in 1 s (FEV1) increased significantly by 15% vs.
    [Show full text]
  • Pharmacology and Therapeutics of Bronchodilators
    1521-0081/12/6403-450–504$25.00 PHARMACOLOGICAL REVIEWS Vol. 64, No. 3 Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics 4580/3762238 Pharmacol Rev 64:450–504, 2012 ASSOCIATE EDITOR: DAVID R. SIBLEY Pharmacology and Therapeutics of Bronchodilators Mario Cazzola, Clive P. Page, Luigino Calzetta, and M. Gabriella Matera Department of Internal Medicine, Unit of Respiratory Clinical Pharmacology, University of Rome ‘Tor Vergata,’ Rome, Italy (M.C., L.C.); Department of Pulmonary Rehabilitation, San Raffaele Pisana Hospital, Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy (M.C., L.C.); Sackler Institute of Pulmonary Pharmacology, Institute of Pharmaceutical Science, King’s College London, London, UK (C.P.P., L.C.); and Department of Experimental Medicine, Unit of Pharmacology, Second University of Naples, Naples, Italy (M.G.M.) Abstract............................................................................... 451 I. Introduction: the physiological rationale for using bronchodilators .......................... 452 II. ␤-Adrenergic receptor agonists .......................................................... 455 A. A history of the development of ␤-adrenergic receptor agonists: from nonselective ␤ Downloaded from adrenergic receptor agonists to 2-adrenergic receptor-selective drugs.................... 455 ␤ B. Short-acting 2-adrenergic receptor agonists........................................... 457 1. Albuterol........................................................................ 457
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • WO 2015/185128 Al 10 December 2015 (10.12.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/185128 Al 10 December 2015 (10.12.2015) P O P C T (51) International Patent Classification: (74) Agent: MINOJA, Fabrizio; BIANCHETTI BRACCO C07D 453/00 (2006.01) A61P 11/06 (2006.01) MINOJA S.r.L, Via Plinio, 63, 1-20129 Milano (IT). A61K 31/4427 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP20 14/06 1602 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (22) International Filing Date: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, 4 June 2014 (04.06.2014) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (25) Filing Language: English KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (26) Publication Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: CHIESI FARMACEUTICI S.P.A. [IT/IT]; SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, Via Palermo, 26/A, 1-43 100 Parma (IT). TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: AMARI, Gabriele; c/o CHIESI FARMA CEUTICI S.p.A, Via Palermo, 26/A, 1-43 100 Parma (FT).
    [Show full text]
  • Drugs with Anticholinergic Properties and Cognitive Performance in the Elderly: Results from the PAQUID Study
    DOI:10.1111/j.1365-2125.2004.02232.x British Journal of Clinical Pharmacology Drugs with anticholinergic properties and cognitive performance in the elderly: results from the PAQUID Study Nathalie Lechevallier-Michel,1 Mathieu Molimard,1 Jean-François Dartigues,2 Colette Fabrigoule2 & Annie Fourrier-Réglat1 1Département de Pharmacologie, EA 3676: Médicaments, Produits et Systèmes de Santé and 2Institut National de la Santé et de la Recherche Médicale, Unité 593, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France Correspondence Objectives Annie Fourrier-Réglat, Département To measure the association between the use of drugs with anticholinergic properties de Pharmacologie, EA 3676: and cognitive performance in an elderly population, the PAQUID cohort. Médicaments, Produits et Systèmes de Santé, Université Victor Segalen Methods Bordeaux 2, 146 rue Léo Saignat, The sample studied was composed of 1780 subjects aged 70 and older, living at 33076 Bordeaux Cedex, France. home in South western France. Data on socio-demographic characteristics, medical Tel: + 33 5 5757 1561 history and drug use were collected using a standardized questionnaire. Cognitive Fax: + 33 5 5757 4660 performance was assessed using the following neuropsychological tests: the Mini- E-mail: [email protected] Mental State Examination (MMSE) which evaluates global cognitive functioning, the bordeaux2.fr Benton Visual Retention Test (BVRT) which assesses immediate visual memory, and the Isaacs’ Set Test (IST) which assesses verbal fluency. For each test, scores were dichotomized between low performance and normal to high performance using the score at the 10th percentile of the study sample as the cut-off point, according to Keywords age, gender and educational level.
    [Show full text]
  • Use of Inhaled Anticholinergic Agents in Obstructive Airway Disease Ruben D Restrepo MD RRT
    Use of Inhaled Anticholinergic Agents in Obstructive Airway Disease Ruben D Restrepo MD RRT Introduction Parasympathetic Regulation Cholinergic Neurotransmitter Function Muscarinic Effects Available Agents Ipratropium Bromide Oxitropium Bromide Tiotropium Bromide Clinical Use of Anticholinergics Stable COPD COPD Exacerbation Adult Asthma Pediatric Asthma Adverse Effects Pharmacoeconomics Summary and Recommendations Conclusion In the last 2 decades, anticholinergic agents have been generally regarded as the first-choice bron- chodilator therapy in the routine management of stable chronic obstructive pulmonary disease (COPD) and, to a lesser extent, asthma. Anticholinergics are particularly important bronchodila- tors in COPD, because the vagal tone appears to be the only reversible component of airflow limitation in COPD. The inhaled anticholinergics approved for clinical use are synthetic quaternary ammonium congeners of atropine, and include ipratropium bromide, oxitropium bromide, and tiotropium bromide. This article reviews the most current evidence for inhaled anticholinergics in obstructive airway disease and summarizes outcomes reported in randomized controlled trials. Key words: anticholinergic, muscarinic receptor, antimuscarinic, chronic obstructive pulmonary disease, COPD, asthma, ipratropium, oxitropium, tiotropium. [Respir Care 2007;52(7):833–851. © 2007 Daeda- lus Enterprises] Introduction medicine for centuries. It is believed that the alkaloid da- turine, extracted from the Datura stramonium plant, was Atropine and scopolamine are naturally occurring anti- identified as atropine in 1833 and was the first pharmaco- cholinergic alkaloids that have been used in traditional Ruben D Restrepo MD RRT is affiliated with the Department of Respi- ratory Care, The University of Texas Health Science Center, San Anto- The author reports no conflicts of interest related to the content of this nio, Texas.
    [Show full text]
  • 1 APPENDICES Appendix 1. Inhalers Included in The
    APPENDICES Appendix 1. Inhalers included in the systematic review ................................................................ 2 Appendix 2. Full list of excluded medications ............................................................................... 4 Appendix 3. All efficacy and safety outcomes considered ............................................................. 5 Appendix 4. Patient ratings of relevant outcomes .......................................................................... 6 Appendix 5. Final MEDLINE Search ............................................................................................. 7 Appendix 6: Included Studies with References for each analysis and sub-group analysis .......... 15 Appendix 7. Characteristics of the randomized controlled trials .................................................. 17 Appendix 8. Patient characteristics ............................................................................................... 26 Appendix 9: Risk of bias results for the included studies ............................................................. 37 Appendix 10. Network Meta-analysis results Outcome ............................................................... 43 Appendix 11. Sensitivity Network Meta-analysis results (only significant) ................................ 78 Appendix 12. SUCRA Values ...................................................................................................... 80 Appendix 13. Forest Plots ............................................................................................................
    [Show full text]
  • Supplementary File
    READ codes for asthma and/or COPD and asthma-COPD overlap in the CPRD Read Code Description/Read Term H331.00 Intrinsic Asthma 66YP.00 Asthma night-time symptoms H330.11 Allergic asthma H330.12 Childhood asthma H330.13 Hay fever with asthma H330.14 Pollen asthma H35y600 Sequoiosis (red-cedar asthma) 663O.00 Asthma not disturbing sleep 9OJB.00 Asthma monitoring invit SMS (short message service) 9NI8.00 Asthma outreach clinic 663e100 Asthma severely restricts exercise 8793.00 Asthma control step 0 9N1d.00 Seen in asthma clinic 2126200 Asthma resolved 173A.00 Exercise induced asthma 66Ys.00 Asthma never causes night symptoms 663t.00 Asthma causes daytime symptoms 1 to 2 times per month 663..11 Asthma monitoring 663q.00 Asthma daytime symptoms H33z000 Status asthmaticus NOS 8798.00 Asthma control step 5 663h.00 Asthma – currently dormant 663n.00 Asthma treatment compliance satisfactory 9OJA.11 Asthma monitored 661M100 Asthma self-management plan agreed 663e.00 Asthma restricts exercise 663V200 Moderate asthma H33..11 Bronchial asthma 388t.00 Royal college of physicians asthma 68C3.00 Asthma screening 9OJ6.00 Asthma monitor 3rd letter 66Yz500 Telehealth asthma monitoring H335.00 Chronic asthma with fixed airflow H330.00 Extrinsic (atopic) asthma 663V300 Severe asthma 1784.00 Asthma trigger – emotion 66YQ.00 Asthma monitoring by nurse 661N100 Asthma self-management plan review 663w.00 Asthma limits walking up hills or stairs 679J000 Health education - asthma self management 663u.00 Asthma causes daytime symptoms 1 to 2 times per week H33z100
    [Show full text]
  • Bronchodilator Reversibility, Exercise Performance and Breathlessness in Stable Chronic Obstructive Pulmonary Disease
    Eur Resplr J 1992, 5, 659-664 Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease J.G. Hay, P. Stone, J. Carter, S. Church, A. Eyre-Brook, M.G. Pearson, A.A. Woodcock, P.M.A. Calverley Bronchodilator reversibility, exercise performance and breathlessness in stable Aintree Chest Centre chronic obstructive pulmonary disease. J.G. Hay, P. Stone, J. Carter, S. Church, Fazakerley Hospital, Liverpool A. Eyre-Brook, M.G. Pearson, A.A. Woodcock, P.M.A. Calverley. Regional Dept of Respiratory Physiology ABSTRACT: Partial bronchodilator reversibility can be demonstrated in many Wythenshawe Hospital, Manchester patients with stable chronic obstructive pulmonary disease (COPD), but its and Boehringer Ingelheim, UK. relevance to exercise capacity and symptoms is uncertain. Previous data suggest that anticholinergic bronchodllators do not improve exercise tolerance Correspondence: P.M.A. Calverley In such patients. Aintree Chest Centre We studied 32 patients with stable COPD, mean age 65 yrs, in a double­ Fazakerley Hospital blind, placebo-controlled, cross-over trial of the inhaled anticholinergic drug, Longmoor Lane oxitropium l;>romide. From the within and between day placebo spirometry, we Liverpool, L9 7 AL derived the spontaneous variation In forced expiratory volume In one second UK ) (FEV1 and forced vital capacity (FVC) of this population (FEV1 140 ml; FVC 390 ml) and considered responses beyond this to be significant. Keywords: Bronchodilator reversibility Oxltroplum bromide increased baseline FEV from 0.70 (0.28) l (mean (sn)) 1 chronic obstructive pulmonary disease to 0.88 (0.36) I. The 6 min walking distance increased by 7% compared with dyspnoea placebo, whilst resting breathlessness scores fell from 2.0 to 1.23 at rest and exercise performance 4.09 to 3.28 at the end of exercise after the active drug.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]
  • A Comparison of Bronchodilating Effects of Salmeterol and Oxitropium Bromide in Stable Chronic Obstructive Pulmonary Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector RESPIRATORY MEDICINE (1998) 92, 354-357 A comparison of bronchodilating effects of salmeterol and oxitropium bromide in stable chronic obstructive pulmonary disease M. CAZZOLA*, M. G. MATERA+, F. DI PERNA”, F. CALDERARO, C. CALIFANO* AND A. VINCIGUERRA* *Division of Pneumology and Allergology and Respiratory Clinical Pharmacology Unit, A. Cardarelli Hospital, Naples, Italy ‘institute of Pharmacology and Toxicology, Medical School, Second Neapolitan University, Naples, Italy Anti-cholinergic agents are generally regarded as the bronchodilator therapy of first choice in the treatment of stable chronic obstructive pulmonary disease (COPD), considering that they may be more effective than in inhaled &agonist. However, results of the authors’ recent studies conflict to some extent with this suggestion because they demonstrate that this is true only for short acting &agonists but not for long-acting P,-agonists. Oxitropium bromide is an anti-cholinergic drug that has been shown to produce a similar degree of bronchodilation to that obtained with ipratropium bromide, but with a longer-lasting effect. In the present study, the time course of inhaled oxitropium bromide bronchodilation in comparison to that of inhaled salmeterol in a group of patients with partially reversible COPD was evaluated. Twelve male patients with moderate to severe COPD participated in the study. The study had a single-bind, cross-over, randomized design. The bronchodilator activity of 5Opg salmeterol hydroxynaphthoate, 200 and 400 pg oxitropium bromide and placebo, which were all inhaled from a metered-dose inhaler, was investigated on several non-consecutive days.
    [Show full text]